Prevalence of comorbidity in chronic HCV‑infection
https://doi.org/10.33667/2078-5631-2021-1-66-70
Abstract
The effect of the comorbid background on the course of the infectious process in chronic HCV infection requires study due to the existence of a risk of progression of liver fibrosis even after the eradication of the virus against the background of concomitant diseases.
Material and methods. The article analyzes the prevalence of various comorbid conditions in 700 patients with chronic HCV infection, who were observed in the hospital of the Botkin in St. Petersburg, an assessment of the mutual influence of the comorbid background and the progression of liver fibrosis in HCV infection was given. To determine the contribution of comorbidity to the course of HCV infection, the odds ratio (OR) parameters were calculated.
Results. HCV-infected individuals have higher prevalence of comorbidity (63 %) and multimorbidity (50 %). In patients with severe fibrosis or cirrhosis, the presence of the comorbidity factor increased to 85 %. In the examined group of patients, diseases of the biliary tract and pancreas prevailed (30.0 %), occult Hepatitis B Infection was revealed in 19.0 %, in 15.4 % – cardiovascular diseases, in 13.7 % – diseases of the upper gastrointestinal tract. Diabetes mellitus was found in 4.6 % of patients, and obesity – in 5.9 %, kidney disease – 3.0 %. The remaining concomitant diseases occurred in less than 2.0 % of the observed patients. It has been established that diseases of the biliary tract and pancreas, gastrointestinal tract, diabetes mellitus, obesity, cardiovascular diseases are risk factors for the development of liver fibrosis in chronic HCV infection.
Conclusions. The data obtained indicate the need for a more personalized approach to monitoring patients and the need to create integrated models of medical care for patients with chronic hepatitis C.
About the Authors
E. V. Esaulenko
Saint Petersburg State Pediatric Medical University; Saint Petersburg Research Institute for Epidemiology and Microbiology n. a. Pasteur
Russian Federation
Russian Federation
Esaulenko Elena V.
Saint Petersburg
K. E. Novak
Saint Petersburg State Pediatric Medical University
Russian Federation
Russian Federation
Novak Kseniya E.
Saint Petersburg
V. V. Basina
Saint Petersburg State Pediatric Medical University
Russian Federation
Russian Federation
Basina Valentina V.
Saint Petersburg
A. A. Dzemova
Saint Petersburg State Pediatric Medical University; Saint Petersburg Research Institute for Epidemiology and Microbiology n. a. Pasteur
Russian Federation
Russian Federation
Dzemova Alexandra A.
Saint Petersburg
R. A. Ganchenko
Saint Petersburg State Pediatric Medical University
Russian Federation
Russian Federation
Ganchenko Roman A.
Saint Petersburg
References
1. Zhdanov K. V., Kozlov K. V., Sukachev V. S., Zaharenko S. M., Karyakin S. S., Saulevich A. V., Lobzin D. Yu., Yaryemenko M. V., Ivanov K. S., Lyashenko Yu.I., Karev V. E., Zaharkiv Yu.F., Bulan’kov Yu. I. Elimination of HCV-infection: a history with continuation. Journal of Infectology. 2018. 10 (4): 6–13. (In Russian)
2. Cooper C. L., Galanakis C., Donelle J., Kwong J. C., Boyd R., Boucher L., Kendall C. E. HCV-infected individuals have higher prevalence of comorbidity and multimorbidity: a retrospective cohort study. BMC Infect Dis. 2019; 19 (1): 712. https://doi.org/10.1186/s12879–019–4315–6.
3. Francesco Negro. Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases. J Hepatol. 2014; 61 (1): 69–78. https://doi.org/10.1016/j.jhep.2014.08.003
4. Novak K. E. Clinical and morphological characteristics of subcompensated and decompensated liver cirrhosis of viral etiology. Pediatrician. 2011. 11 (2): 47–52. (In Russian)
5. Kuna L., Jakab J., Smolic R., Wu GY, Smolic M. HCV Extrahepatic Manifestations. Journal of Clinical and Translational Hepatology 2019; 7 (2): 172–182. https://doi.org/10.14218/JCTH.2018.00049
6. Yan FM., Chen A. S., Hao F., Zhao X. P., Gu Ch.H., Zhao L. B., Yang D. L., Hao L. J. Hepatitis C virus may infect extrahepatic tissues in patients with hepatitis C. World J Gastroenterol. 2000; 6 (6): 805–811. https://doi.org/10.3748/wjg.v6.i6.805
7. Viral hepatitis in the Russian Federation. An analytical review. Ussue 11. Ed. V. I. Pokrovsky, A. A. Totolian. SPb: Saint-Petersburg Paster Institute, 2018. 112 p. (In Russ.)
8. Babinets L. S., Shaihen O. R., Homyn H. O., Halabitska I. M. Specific aspects of clinical course in case of combination of chronic pancreatitis and concomitant viral hepatitis. Wiad Lek. 2019; 72 (4): 595–599.
9. Acalovschi M., Buzas C., Radu C., Grigorescu M. Hepatitis C virus infection is a risk factor for gallstone disease: a prospective hospital-based study of patients with chronic viral C hepatitis. J Viral Hepat. 2009; 16 (12): 860–6. https://doi.org/10.1111/j.1365–2893.2009.01141.x.
10. Wijarnpreecha K., Thongprayoon Ch., Panjawatanan P., Lekuthai N., Ungprasert P. Hepatitis C virus infection and risk of gallstones: A meta-analysis. J Evid Based Med. 2017; 10(4): 263–270. https://doi.org/10.1111/jebm.12277.
11. Labenz С., Huber Y., Kalliga E., Nagel M., Ruckes C., Straub B. K., Galle P. R., Wörns M-A, Anstee Q. M., Schuppan D., Schattenberg J. M. Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany. Aliment Pharmacol Ther. 2018; 48 (10): 1109–1116. https://doi.org/10.1111/apt.14976.
12. Cherkashchenko N. A., Livzan M.A, Krolevets T. S. Clinical features of the comorbid course of non-alcoholic fatty liver disease and gallstone disease. Ter Arkh. 2020; 92 (8): 29–36. DOI: 10.26442/00403660.2020.08.000764.
13. Coppola N, Onorato L, Pisaturo M, Macera M, Sagnelli C, Martini S, Sagnelli E. Role of occult hepatitis B virus infection in chronic hepatitis C. World J Gastroenterol. 2015; 21 (42): 11931–40. DOI: 10.3748/wjg.v21.i42.11931.
14. Habibollahi P., Safari S., Daryani N. E., Alavian S. M. Occult Hepatitis B Infection and its Possible Impact on Chronic Hepatitis C Virus Infection. Saudi J Gastroenterol. 2009; 15 (4): 220–224. DOI: 10.4103/1319–3767.56089.
15. Dore M. P., Mura D., Deledda S., Maragkoudakis E., Pironti A., Realdi G. Active peptic ulcer disease in patients with hepatitis C virus-related cirrhosis: the role of Helicobacter pylori infection and portal hypertensive gastropathy. Can J Gastroenterol. 2004; 18 (8): 521–4. DOI: 10.1155/2004/150674.
16. Wang J., Li W. T., Zheng Y. X., Zhao S. S., Li N., Huang Y., Zhou R. R., Huang Z. B., Fan X. G. The Association between Helicobacter pylori Infection and Chronic Hepatitis C: A Meta-Analysis and Trial Sequential Analysis. Gastroenterol Res Pract. 2016; 2016: 8780695. DOI: 10.1155/2016/8780695.
17. Chung J. W., Choi H. Y., Ki M., Jang E. S., Jeong S. H. Comorbidities and Prescribed Medications in Korean Patients with Chronic Hepatitis C: A Nationwide, Population-Based Study. Gut Liver. 2020. DOI: 10.5009/gnl19387.
18. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C. 2018. J. Hepatol. 2018, Vol. 69, No. 2. pp. 461–511. DOI: 10.1016/j.jhep.2018.03.026.
19. Vezali E., Elefsiniotis I., Mihas C., Konstantinou E., Saroglou G. Thyroid dysfunction in patients with chronic hepatitis C: virus- or therapy-related? J. Gastroenterol. Hepatol. 2009; 24 (6): 1024–9.
20. Nikonorova M. A., Lubskaya N. S., Volchkova E. V., Nemilostiva E. A. Variants of thyroid gland pathology in chronic hepatitis C Epidemiology and Infectious Diseases. 2017; 22 (4): 172–177.
21. Vernon G., Baranova A., Younossi Z. M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and nonalcoholic steatohep atitis in adults. Aliment Pharmacol. Ther. 2011. 34: 274–285.
22. Ivashkin V. T., Drapkina O. M., Mayev I. V., Trukhmanov A. S., D. V. Blinov D. V., L. K. Palgova L. K., Tsukanov V. V., Ushakova T. I. Prevalence of non-alcoholic fatty liver disease in out-patients of the Russian Federation: DIREG 2 study results. The Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016; 25 (6): 31–41 (In Russ.)
23. Novak K. E., Karev V. E., Dunaeva N. V., Esaulenko E. V. Postmortem morpholog ical characteristics in patients with chronic viral hepatitis with clinical signs of cirrhosis Russian Medical Journal, No. 2, 2011, P. 8–11 (In Russ.)
24. Fabrizi F., Donato F. M., Messa P. Association between Hepatitis C Virus and Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Annals of Hepatology. 2018; 17 (3): 364–391. https://doi.org/10.5604/01.3001.0011.7382
25. Pol S., Vallet-Pichard A., Hermine O. Extrahepatic cancers and chronic HCV infection. Nat Rev Gastroenterol Hepatol. 2018; 15 (5): 283–290. DOI: 10.1038/nrgastro.2017.172.
26. Masarone M, Persico M. Hepatitis C virus infection and non-hepatocellular malignancies in the DAA era: a systematic review and meta-analysis. Liver Int. 2019. 39 (7): 1292–1306.
27. Cacoub P., Comarmond C., Domont F., Savey L., Desbois AC, Saadoun D. Ex trahepatic manifestations of chronic hepatitis C virus infection. Ther Adv Infect Dis. 2016. 3 (1): 3–14. DOI: 10.1177/2049936115585942.
28. Novak K. E., Karev V. E., Dunaeva N. V., Esaulenko E. V. Comparative morpholog ical characterization of viral and viral-alcoholic liver cirrhosis (based on autopsy data). Vestnik NovSU. 2011. No. 62. P. 137–140.
29. Adinolfi L. E., Nevola R., Lus G., Restivo L., Guerrera B., Romano C., Zampino R., Rinaldi L., Sellitto A., Giordano M., Marrone A. Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview. World J Gastroenterol. 2015; 21 (8): 2269–80. DOI: 10.3748/wjg.v21.i8.2269.
Review
For citations:
Esaulenko E.V., Novak K.E., Basina V.V., Dzemova A.A., Ganchenko R.A. Prevalence of comorbidity in chronic HCV‑infection. Medical alphabet. 2021;(1):66-70. (In Russ.) https://doi.org/10.33667/2078-5631-2021-1-66-70
Views:
626
Email this article 